Mallinckrodt Public Limited Company Debt to Equity Ratio 2012-2018 | MNK

Current and historical debt to equity ratio values for Mallinckrodt Public Limited Company (MNK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Mallinckrodt Public Limited Company debt/equity for the three months ending September 30, 2018 was 0.93.
Mallinckrodt Public Limited Company Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $6.17B $6.60B 0.94
2018-06-30 $6.34B $6.47B 0.98
2018-03-31 $6.49B $6.46B 1.01
2017-12-31 $6.42B $6.52B 0.98
2017-09-30 $5.52B $5.11B 1.08
2017-06-30 $5.34B $5.10B 1.05
2017-03-31 $5.70B $5.11B 1.12
2016-12-31 $5.88B $4.98B 1.18
2016-09-30 $0.00B $0.00B 0.00
2016-06-30 $6.28B $5.21B 1.21
2016-03-31 $6.41B $5.10B 1.26
2015-12-31 $6.41B $5.19B 1.23
2015-09-30 $6.47B $5.31B 1.22
2015-06-30 $5.33B $5.30B 1.01
2015-03-31 $3.97B $5.19B 0.77
2014-12-31 $3.94B $5.07B 0.78
2014-09-30 $3.95B $4.96B 0.80
2014-06-30 $2.20B $1.33B 1.66
2014-03-31 $2.21B $1.34B 1.65
2013-12-31 $0.92B $1.31B 0.70
2013-09-30 $0.92B $1.26B 0.73
2013-06-30 $0.92B $1.16B 0.79
2013-03-31 $0.00B $0.00B 0.00
2012-12-31 $0.00B $0.00B 0.00
2012-09-30 $0.01B $1.89B 0.01
2012-06-30 $0.00B $0.00B 0.00
2011-09-30 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.571B $3.222B
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.085B 9.11
Teva Pharmaceutical Industries (TEVA) Israel $22.626B 6.93
Mylan (MYL) United Kingdom $18.006B 7.41
Bausch Health Cos (BHC) Canada $8.859B 6.41
Dr Reddy's Laboratories (RDY) India $5.791B 23.13
Supernus Pharmaceuticals (SUPN) United States $2.296B 21.75
Amphastar Pharmaceuticals (AMPH) United States $0.953B 103.35
Akorn (AKRX) United States $0.860B 0.00
Homology Medicines (FIXX) United States $0.769B 0.00
Assembly Biosciences (ASMB) United States $0.628B 0.00
CymaBay Therapeutics (CBAY) United States $0.574B 0.00
Corium (CORI) United States $0.459B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.455B 0.00
Voyager Therapeutics (VYGR) United States $0.405B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.296B 0.00
Teligent (TLGT) United States $0.137B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.093B 0.00
Aevi Genomic Medicine (GNMX) United States $0.071B 0.00
Acasti Pharma (ACST) Canada $0.057B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.029B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00